Comparative Pharmacology
Head-to-head clinical analysis: KENALOG IN ORABASE versus PREDNISONE INTENSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENALOG IN ORABASE versus PREDNISONE INTENSOL.
KENALOG IN ORABASE vs PREDNISONE INTENSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, suppress immune response, and inhibit fibroblast proliferation.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression to produce anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Apply a thin layer to the affected area 2-4 times daily, after meals and at bedtime. Do not rub in; allow to form a film.
5-60 mg orally once daily or divided twice daily, titrated to response.
None Documented
None Documented
Terminal half-life approximately 2-5 hours following mucosal application.
2-4 hours (terminal) for prednisone; prednisolone half-life 2-4 hours. Clinical context: shorter than anti-inflammatory effect due to delayed receptor-mediated action.
Primarily hepatic metabolism; metabolites excreted renally (~75%) and in feces (~10%).
Renal: <30% unchanged; major metabolites (prednisolone, 20-dihydroprednisolone) conjugated and excreted in urine. Fecal: <10%.
Category C
Category D/X
Corticosteroid
Corticosteroid